PET/CT-biopsi studyA PET/CT biopsy study in patients Capecitabine +/- Sorafenib in the treatment of locally advanced or metastatic HER2-negative breast cancer.
- Conditions
- Morphological verifications of metastatic lesions, PET Ribonucleic Acid (RNA)-expression study in subjects with locally advance or metastatic HER2-negative breast cancer.MedDRA version: 14.1Level: LLTClassification code 10004244Term: Benign breast neoplasm NOSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
- Registration Number
- EUCTR2012-002053-29-SE
- Lead Sponsor
- Karolinska Institutet and University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- Female
- Target Recruitment
- Not specified
Inclusion Criteria
Signed Informed Consent for participation in the trial 12444 with EudraCT number 2012-018501-10.
Signed Informed Consent for this trial.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 10
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 10
Exclusion Criteria
Not defined.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method